Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Saved in:
| Title: | Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. |
|---|---|
| Authors: | Goldberg, Sarah B1 sarah.goldberg@yale.edu, Gettinger, Scott N1, Mahajan, Amit1, Chiang, Anne C1, Herbst, Roy S1, Sznol, Mario1, Tsiouris, Apostolos John2, Cohen, Justine1, Vortmeyer, Alexander1, Jilaveanu, Lucia1, Yu, James1, Hegde, Upendra3, Speaker, Stephanie1, Madura, Matthew1, Ralabate, Amanda1, Rivera, Angel1, Rowen, Elin1, Gerrish, Heather1, Yao, Xiaopan1, Chiang, Veronica1 |
| Source: | Lancet Oncology. Jul2016, Vol. 17 Issue 7, p976-983. 8p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
